Managed Care
Disease
Management

New Hepatitis C drugs: A balancing act of costs and benefits

In the rapidly evolving market for hepatitis C virus treatments, much more effective medications with higher price tags will require careful cost-benefit analyses, says F. Randy Vogenberg, PhD, RPh.

Meetings

HealthIMPACT Southeast Tampa, FL January 23, 2015